The stock may face downward pressure due to the significant revenue decline and sustained losses. However, traders should monitor the progress of the two new FDA submissions as potential catalysts for future growth. The continued share buyback provides some support, but the weak guidance for Q1 2026 suggests the turnaround will take time.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $3.08entry
- T+1 · 9mo ago +2.27%α +2.73% · $3.15
- T+5 · 9mo ago −2.92%α −1.79% · $2.99
- T+20 · 8mo ago −0.32%α +6.08% · $3.07
- T+60 · 6mo ago +6.82%α −0.93% · $3.29
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OraSure Technologies reported a significant decline in Q4 and full-year 2025 revenue, down 29% and 38% respectively, driven by steep drops in its core diagnostics and sample management businesses. Despite the poor financial performance, the company highlighted new FDA submissions for a Chlamydia/Gonorrhea self-test and a urine collection device, and maintained a $40 million share buyback program. The filing presents a mixed picture of deteriorating fundamentals offset by future growth initiatives.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $26.8 million, down 29% YoY; full-year revenue was $115 million, down 38% YoY.
- Core business revenue (excluding COVID-19) declined 22% YoY in Q4 and 14% for the full year.
- GAAP net loss was $19.3 million for Q4 and $68.7 million for the full year.
- Company submitted two new applications to the FDA in December 2025 for a rapid molecular self-test for Chlamydia/Gonorrhea and a Colli-Pee at-home urine collection device.
- Company deployed $5 million to repurchase 1.9 million shares in Q4 and has $25 million remaining on its $40 million buyback program.
- Q1 2026 revenue guidance is $26-$29 million, indicating no immediate recovery.
Financial Impact
Revenue declined by $10.7 million in Q4 and $70.8 million for the full year, with a net loss of $68.7 million for the year.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Core Business | $26.7M | -22.0% |
| Diagnostics | $15.1M | -20.0% |
| Sample Management Solutions | $9.1M | -39.0% |
Risk Factors
- Continued revenue decline in core business segments.
- Failure to gain FDA approval for new product submissions.
- High operating losses may deplete cash reserves despite strong balance sheet.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001116463-26-000009 |
| Exhibit: exhibit992_q4-25investor.htm | 0001116463-26-000009 |
| Document: osur-20260225.htm | 0001116463-26-000009 |
| Document: 0001116463-26-000009-index-headers.html | 0001116463-26-000009 |
| Document: 0001116463-26-000009-index.html | 0001116463-26-000009 |
| Document: 0001116463-26-000009.txt | 0001116463-26-000009 |
| CONTEXT: Previous Earnings (2026-02-25) | 0001116463-26-000009 |
Track record
20 reports on OSUR
6 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +39.73% at T+60 after the Mar 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 10-Q/A Neutral 2/10 Entry $3.62 to $3.62 Now $3.60 −0.55% · 0.00% +0.36% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $3.33 to $3.56 Now $3.60 +8.11% ▲ +6.91% +5.59% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $3.53 to $3.33 Now $3.60 +1.98% ▼ −5.67% −5.30% vs SPY
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $3.46 to $3.53 Now $3.60 +4.20% ▲ +2.17% +1.87% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $3.94 to $3.46 Now $3.60 −8.63% ▼ −12.31% −11.83% vs SPY
- Sep 17, 20268w ago SC 13D Bullish 6/10 Entry $3.56 to $3.69 Now $3.60 +1.12% ▲ +3.65% +2.10% vs SPY
- Jul 23, 202616w ago Court Ruling Neutral 3/10 Entry $3.97 to $3.96 Now $3.60 −9.32% ▼ −0.25% −0.27% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 4/10 Entry $4.18 to $4.17 Now $3.60 −13.88% ▼ −0.24% −2.00% vs SPY
- Jun 3, 202623w ago 8-K Neutral 3/10 Entry $4.17 to $4.04 Now $3.60 −13.67% ▼ −3.12% −0.52% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $3.13 to $3.06 Now $3.60 −15.02% ▲ +2.24% +3.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers